Evidence map›Paper›PMID 21303308›Full record

ArticleExpert opinion on investigational drugs2011

Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.

Sabina Antonela Antoniu

Abstract readComment
PubMed Publisher
In one paragraph

Article in Expert opinion on investigational drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Sabina Antonela AntoniuUniversity of Medicine and Pharmacy Gr. T. Popa Iasi, Pulmonary Disease University Hospital, Department of Internal Medicine II-Pulmonary Disease, 30 Dr I Cihac Str., Iasi, Romania. sabina.antonela.antoniu@pneum.umfiasi.ro
Grigore T. Popa University of Medicine and Pharmacy · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSeveral types of mutations in the cystic fibrosis transmembrane regulator (CFTR) gene lead to abnormal CFTR protein and alterations of chloride and sodium transmembrane transportation in cystic fibrosis (CF). Some investigational compounds such as VX-770 can improve CFTR protein function. AREAS COVERED: This paper discusses the results of a Phase II study investigating the safety and efficacy of VX-770 in patients with CF. EXPERT OPINION: VX-770 is able to improve chloride and sodium transportation and has a good safety profile. Although such compounds have limited therapeutic targeting potential, preliminary results show great promise in the context of CF therapy.

Indexed as

AminophenolsCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorQuinolonesAdolescentAdultAgedAged, 80 and overCell MembraneClinical Trials, Phase II as TopicControlled Clinical Trials as TopicDouble-Blind MethodHumansIon TransportMiddle AgedMulticenter Studies as TopicAminophenolsCystic Fibrosis Transmembrane Conductance RegulatorivacaftorQuinolones

Identifiers

PMID21303308
OpenAlexW2106113444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.